Palo Santo

WELCOME

ShapingShaping

thethe

FutureFuture

ofof

MentalMental

Health.Health.

Palo Santo invests in next-generation neuroscience companies developing breakthrough therapeutics and technologies for mental health.

THE TIME IS NOW

Transforming Mental Health
Through Next-Generation
Neuroscience Targets and
Psychedelic Therapeutics

LEARN WHY

Core investments

23 core investments across neuroscience therapeutics and technologies

Strategic
Biopharma
Partnerships

Partnerships across leading pharmaceutical and biotechnology companies, including AbbVie's $1.2B acquisition of Gilgamesh's lead program

FDA Breakthrough Therapy Designations

Eight FDA Breakthrough Therapy Designations in psychedelic medicine

350⁺

Clinical Trials

Over 350 FDA clinical trials involving psychedelics in progress worldwide

Core investments

23 core investments across neuroscience therapeutics and technologies

Strategic Biopharma Partnerships

Partnerships across leading pharmaceutical and biotechnology companies, including AbbVie's $1.2B acquisition of Gilgamesh's lead program

Breakthrough Therapy Designations

Eight FDA Breakthrough Therapy Designations in psychedelic medicine

350⁺

Clinical Trials

Over 350 FDA clinical trials involving psychedelics in progress worldwide

Portfolio.

From next-generation psychedelics to novel CNS targets and enabling technologies, our portfolio spans the forefront of neuroscience innovation driving new treatments for mental health

Building the Future Of Brain Health with AI-Driven Neurotechnology

Learn More

Helping Patients with Neurological & Psychiatric Disorders through Innovative Psychedelic Pharmaceuticals.

Learn More

Novel Psychedelic Analogues For the Treatment of Neuropsychiatric Conditions

Learn More

Revolutionizing short-duration psychedelic therapies for underserved medical conditions

Learn More

Reimagining brain health through new insights into synaptic biology

Learn More

Full Portfolio